[go: up one dir, main page]

WO2001060985A3 - Compositions, methods and kits relating to uridine phosphorylase gene mutations - Google Patents

Compositions, methods and kits relating to uridine phosphorylase gene mutations Download PDF

Info

Publication number
WO2001060985A3
WO2001060985A3 PCT/US2001/004683 US0104683W WO0160985A3 WO 2001060985 A3 WO2001060985 A3 WO 2001060985A3 US 0104683 W US0104683 W US 0104683W WO 0160985 A3 WO0160985 A3 WO 0160985A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleotide
uridine phosphorylase
methods
compositions
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/004683
Other languages
French (fr)
Other versions
WO2001060985A9 (en
WO2001060985A2 (en
Inventor
Giuseppe Pizzorno
Deliang Cao
Dekai Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Priority to AU2001236990A priority Critical patent/AU2001236990A1/en
Publication of WO2001060985A2 publication Critical patent/WO2001060985A2/en
Publication of WO2001060985A3 publication Critical patent/WO2001060985A3/en
Anticipated expiration legal-status Critical
Publication of WO2001060985A9 publication Critical patent/WO2001060985A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention relates to human uridine phosphorylase nucleic acids and proteins encoded thereby. More specifically, the invention discloses that uridine phosphorylase in certain tumor tissues is resistant to inhibition by uridine phosphorylase inhibitor (UPI). The invention further relates to identification of mutations associated with uridine phosphorylase resistance to UPIs. These mutations include mutations located in exon 1 and exon 6. More specifically, the mutations include, but are not limited to, a change from a C to T at nucleotide 40, a C to T at nucleotide 135, a C to G at nucleotide 178, an A to C at nucleotide 182, a C to T at nucleotide 186, a G to A at nucleotide 713, and a G to A at nucleotide 752. The invention also relates to methods and kits relating to the nucleic and amino encoding UPase resistant to UPIs and uses therefor.
PCT/US2001/004683 2000-02-14 2001-02-14 Compositions, methods and kits relating to uridine phosphorylase gene mutations Ceased WO2001060985A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001236990A AU2001236990A1 (en) 2000-02-14 2001-02-14 Compositions, methods and kits relating to uridine phosphorylase gene mutations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18227300P 2000-02-14 2000-02-14
US60/182,273 2000-02-14

Publications (3)

Publication Number Publication Date
WO2001060985A2 WO2001060985A2 (en) 2001-08-23
WO2001060985A3 true WO2001060985A3 (en) 2002-01-17
WO2001060985A9 WO2001060985A9 (en) 2002-10-31

Family

ID=22667757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004683 Ceased WO2001060985A2 (en) 2000-02-14 2001-02-14 Compositions, methods and kits relating to uridine phosphorylase gene mutations

Country Status (2)

Country Link
AU (1) AU2001236990A1 (en)
WO (1) WO2001060985A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001169684A (en) 1999-12-17 2001-06-26 Taiho Yakuhin Kogyo Kk Animals lacking uridine phosphorylase expression
EP1651674B1 (en) * 2003-08-14 2010-09-29 Exelixis, Inc. Ups as modifiers of the beta catenin pathway and methods of use
CN111748537B (en) * 2020-08-04 2021-11-26 浙江华睿生物技术有限公司 Uridine phosphatase mutant and application thereof
EP4262804A4 (en) * 2020-12-18 2025-02-12 Codexis, Inc. MANIPULATED ENZYMES WITH URIDINE PHOSPHORYLASE VARIANT

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAO ET AL.: "Effects of a point mutation in the active site of uridine phosphorylase on its enzyme activity, kinetics and BAU inhibition", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 41, March 2000 (2000-03-01), pages 156, XP001010490 *
WATANABE ET AL.: "Cloning and expression of human uridine phosphorylase", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 216, no. 1, 1995, pages 265 - 272, XP001010461 *
WATANABE ET AL.: "Purification, cloning and expression of murine uridine phosphorylase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 20, 1995, pages 12191 - 12196, XP001010484 *
ZHANG ET AL.: "Uridine phosphorylase gene mutations in human breast cancers: PCR-SSCP determination", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 41, March 2000 (2000-03-01), pages 156 - 157, XP001010491 *

Also Published As

Publication number Publication date
AU2001236990A1 (en) 2001-08-27
WO2001060985A9 (en) 2002-10-31
WO2001060985A2 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
WO2002085940A3 (en) New polynucleotides and polypeptides of the erythropoietin gene
PT917571E (en) GENE RELATED TO AGOUTI
WO1999047669A3 (en) Human nucleic acid sequences from tissue of breast tumors
WO2001055178A3 (en) Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
WO2002077171A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002079249A3 (en) New polynucleotides and polypeptides of the ifn$g(a)-21 gene
WO2002086156A3 (en) New polynucleotides and polypeptides of the ifn$g(a)-17 gene
WO2001060985A3 (en) Compositions, methods and kits relating to uridine phosphorylase gene mutations
WO2002095067A3 (en) INTERFERON α-14 POLYMORPHISM
WO2001072977A3 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
WO2003000896A3 (en) POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE
WO2003048303A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002101048A3 (en) NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-7 GENE
BR0109258A (en) Enzymes involved in triterpene synthesis
WO2002083733A3 (en) Polynucleotides and polypeptides of the ifnalpha-6 gene
WO2002016567A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2001088148A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002053717A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002033058A3 (en) Novel cysteine proteases and uses thereof
EP1201680A3 (en) Tumor suppressor polypeptide issued from CHC1-L (chromosome condensation 1-like)
WO2002068617A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
IL159384A0 (en) Immunological binding molecules inhibiting the syncytial fusion of trophoblast cells
WO2005019407A3 (en) Polynucleotides, polypeptides and antibodies and use thereof in treating tsg101-associated diseases
WO2002034901A8 (en) Protein kinase
WO2002061062A3 (en) Human protein kinase n-like polypeptide and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP